“We are starting the fiscal year strong with more than $103 million in revenue, growth of 17%, coming in ahead of our guidance of $100 to $101 million,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST). “We’re encouraged by our overall revenue growth as well as the momentum from DNA Synthesis and Protein Solutions and NGS Applications. Excluding one large NGS Applications customer who is transitioning their assay from research to commercial, NGS Applications revenue grew 18% compared to same period of the year prior. We see continued momentum and reacceleration of the NGS segment as expected moving into our fiscal second quarter.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Private Markets: Anthropic raising $10B at $350B valuation
- Twist Bioscience price target raised to $43 from $32 at TD Cowen
- Twist Bioscience price target raised to $42 from $34 at Evercore ISI
- Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold
- Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets